Patents Assigned to ViroMed Co., Ltd.
-
Publication number: 20190085092Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.Type: ApplicationFiled: August 30, 2016Publication date: March 21, 2019Applicants: bluebird bio, Inc., ViroMed Co., LTD.Inventors: Richard MORGAN, Kevin FRIEDMAN, Seung Shin YU, Jae-Gyun JEONG, Jin-A CHAE
-
Patent number: 10058583Abstract: The present invention relates to a composition for preventing or treating neurological diseases including an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of Euphoria longan fruit, red sage and Gastrodia elata is used as the active ingredient.Type: GrantFiled: March 29, 2012Date of Patent: August 28, 2018Assignee: VIROMED CO., LTD.Inventors: Doo Suk Lee, Dong Sik Kim, Seon Hee Kim
-
Patent number: 9963493Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.Type: GrantFiled: March 27, 2012Date of Patent: May 8, 2018Assignee: VIROMED CO., LTD.Inventors: Jong Mook Kim, Jae Gyun Jeong
-
Patent number: 9404090Abstract: The invention relates to a cell line in which an expression construct is introduced into genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus El coding gene sequence of SEQ ID NO: 32 operatively linked to the promoter. The cell line of the invention is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the invention shows superior adenovirus producing ability, as compared with an HEK 293 cell which is one of conventional adenovirus producing cell lines.Type: GrantFiled: November 22, 2012Date of Patent: August 2, 2016Assignee: VIROMED CO., LTD.Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
-
Patent number: 9131722Abstract: The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum, and reducing the level of Th2 cytokines and IgE in serum.Type: GrantFiled: August 22, 2003Date of Patent: September 15, 2015Assignee: VIROMED CO., LTD.Inventors: Bong Cheol Kim, Mi Rim Jin, Eun Jin Park, Hyung Jin Jung, Sung Seup Shin, Jin Hwan Oh, Hwa Jun Lee, Sun Young Kim, Hyang Jeon
-
Publication number: 20140296142Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.Type: ApplicationFiled: March 27, 2012Publication date: October 2, 2014Applicant: VIROMED CO., LTDInventors: Jong Mook Kim, Jae Gyun Jeong
-
Patent number: 8716446Abstract: The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.Type: GrantFiled: August 21, 2009Date of Patent: May 6, 2014Assignees: Biopolymed Inc., Viromed Co., Ltd.Inventors: Yuni Jung, Seong-Hyun Ho, Myung-Ok Park, Myoung-Suk Kim
-
Publication number: 20140023677Abstract: The present invention relates to a composition for preventing or treating neurological diseases including an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of Euphoria longan fruit, red sage and Gastrodia elata is used as the active ingredient.Type: ApplicationFiled: March 29, 2012Publication date: January 23, 2014Applicant: Viromed Co., Ltd.Inventors: Doo Suk Lee, Dong Sik Kim, Seon Hee Kim
-
Patent number: 8445268Abstract: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.Type: GrantFiled: February 12, 2010Date of Patent: May 21, 2013Assignee: ViroMed Co., Ltd.Inventors: Joon Youb Lee, Dong-Hyeon Kim, Yeonseok Chung, Sun-Young Chang, Kyung-Chul Lee, Chang-Yuil Kang
-
Publication number: 20130122128Abstract: Provided is a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.Type: ApplicationFiled: December 19, 2012Publication date: May 16, 2013Applicant: VIROMED CO., LTD.Inventor: VIROMED CO., LTD
-
Patent number: 8394426Abstract: The present invention relates to a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.Type: GrantFiled: August 25, 2010Date of Patent: March 12, 2013Assignee: Viromed Co., Ltd.Inventors: Bongcheol Kim, Hwa-Jun Lee, Mirim Jin, Hyung-Jin Jung, Sunyoung Kim
-
Patent number: 8389492Abstract: The present invention provides for a method of treating or preventing ischemic or liver disease in a subject by administering a composition reconstituted from a lyophilized hepatocyte growth factor (HGF) DNA formulation, where the DNA formulation comprises an HGF plasmid DNA, salt and a carbohydrate. The invention further provides for a method of making such a lyophilized DNA formulation that preserves or enhances gene expression both in vitro and in vivo, thus maintaining or stimulating the biological activity of the expressed protein. The invention also provides for the DNA formulation, or the lyophilized DNA formulation according to the methods disclosed.Type: GrantFiled: March 10, 2011Date of Patent: March 5, 2013Assignee: ViroMed Co., Ltd.Inventors: Jong-Mook Kim, Sujeong Kim, Woong Hahn, WonSun Yoo
-
Patent number: 8338385Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.Type: GrantFiled: October 20, 2010Date of Patent: December 25, 2012Assignee: ViroMed Co., Ltd.Inventors: Jong-Mook Kim, Woong Hahn
-
Patent number: 8106158Abstract: The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.Type: GrantFiled: April 28, 2009Date of Patent: January 31, 2012Assignee: ViroMed Co., Ltd.Inventors: Sujeong Kim, Jong-Mook Kim, Song Shan Xu
-
Patent number: 8105575Abstract: The present invention relates to the use of internal promoters in mammalian expression vectors including plasmid vectors and enhancer-deleted retroviral vectors. The retroviral vectors have improved safety and optimal levels of transgene expression and vector titers.Type: GrantFiled: October 10, 2007Date of Patent: January 31, 2012Assignee: Viromed Co., Ltd.Inventors: Sunyoung Kim, Sujeong Kim, Jun-Tae Lee
-
Publication number: 20120010273Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.Type: ApplicationFiled: October 20, 2010Publication date: January 12, 2012Applicant: ViroMed Co., Ltd.Inventors: Jong-Mook KIM, Woong Hahn
-
Publication number: 20100330214Abstract: The present invention relates to a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.Type: ApplicationFiled: August 25, 2010Publication date: December 30, 2010Applicant: VIROMED CO., LTD.Inventors: Bongcheol KIM, Hae Kwan Eo, Hwa-Jun Lee, Mirim Jin, Hyung-Jin Jung, Sunyoung Kim
-
Patent number: 7838505Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.Type: GrantFiled: December 14, 2007Date of Patent: November 23, 2010Assignee: ViroMed Co., Ltd.Inventors: Jong-Mook Kim, Woong Hahn
-
Patent number: 7812146Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.Type: GrantFiled: September 20, 2004Date of Patent: October 12, 2010Assignee: ViroMed Co., Ltd.Inventors: Jong-Mook Kim, Woong Hahn, Eun-Jin Park
-
Publication number: 20100210714Abstract: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.Type: ApplicationFiled: February 12, 2010Publication date: August 19, 2010Applicant: ViroMed Co., Ltd.Inventors: Joon Youb LEE, Dong-Hyeon Kim, Yeonseok Chung, Sun-Young Chang, Kyung-Chul Lee, Chang-Yuil Kang